Retatrutide, a groundbreaking dual-acting glucose-dependent incretin analog, represents a significant leap in peptide therapeutics for the treatment of type 2 diabetic conditions and, increasingly, weight issues. Unlike many existing treatment interventions, retatrutide combines the actions of a GLP-1 receptor agonist and a GIP receptor activator,